...
首页> 外文期刊>Liver international : >Biliary dysplasia in patients with primary sclerosing cholangitis: Additional value of DNA ploidity
【24h】

Biliary dysplasia in patients with primary sclerosing cholangitis: Additional value of DNA ploidity

机译:原发性硬化性胆管炎患者的胆道异型增生:DNA倍性的附加价值

获取原文
获取原文并翻译 | 示例

摘要

Background: Detection of biliary dysplasia in PSC is essential for proper timing of liver transplantation to prevent the development of cholangiocancer, which is considered a contraindication for liver transplantation in most centres. In patients with PSC, differential diagnosis of benign, premalignant and malignant biliary strictures is difficult. Aims: This prospective study aimed to evaluate the role of DNA analysis in combination with brush cytology, scored ERCP findings, and tumour markers to detect hepatobiliary dysplasia and malignancy. Material and methods: Brush samples for cytology and for evaluation of DNA content analysed with flow cytometry came from 102 consecutive PSC patients referred for ERCP. Symptoms, serum Ca19-9 and CEA were determined at the time of index biliary examination. ERCP findings were scored for intra- and extrahepatic changes. The end-points were liver transplantation or diagnosis of malignancy or dysplasia. Results: Most of the patients were asymptomatic at the time of ERCP: 73% had no symptoms, and 12% had only mild symptoms. An aneuploid DNA content was evident in 20 (20%) patients, and cells suspected for malignancy in 22 (21%). Seven patients had both aneuploidity and cytology (7%) suspicious for malignancy. An end-point, diagnosis of malignancy or liver transplantation was achieved in 42 patients. Combining DNA ploidity and cytology in patients at the end-point, sensitivity was 72%, specificity 82%, positive predictive value 86% and negative predictive value 67%. Discussion and conclusion: In this mostly asymptomatic PSC-patient population, 33% demonstrated abnormal brush cytology or aneuploidity. Determining DNA ploidy and brush cytology during ERCP offers a useful tool for identifying those PSC patients who are at high risk of developing cholangiocancer.
机译:背景:PSC中胆管异型增生的检测对于适当的肝移植时机至关重要,以预防胆管癌的发展,在大多数中心,胆管癌被认为是肝移植的禁忌症。在PSC患者中,很难对良性,恶性前和恶性胆道狭窄进行鉴别诊断。目的:这项前瞻性研究旨在评估DNA分析与刷细胞学,ERCP评分结果以及肿瘤标志物检测肝胆异型增生和恶性肿瘤的作用。材料和方法:用于细胞学和评估流式细胞仪分析的DNA含量的画笔样品来自102例接受ERCP治疗的连续PSC患者。在进行指标胆道检查时确定症状,血清Ca19-9和CEA。对ERCP的发现进行肝内和肝外变化评分。终点是肝移植或诊断为恶性或不典型增生。结果:大多数患者在ERCP时无症状:73%没有症状,而12%仅是轻度症状。非整倍体DNA含量在20(20%)患者中明显,而怀疑为恶性的细胞在22(21%)中。 7例患者有非整倍性和细胞学检查(7%)可疑为恶性肿瘤。终点诊断为恶性或肝移植的42例患者。结合患者的DNA倍性和细胞学检查,敏感性为72%,特异性为82%,阳性预测值为86%,阴性预测值为67%。讨论与结论:在大多数无症状PSC患者中,有33%表现出异常的刷细胞学或非整倍性。在ERCP期间确定DNA倍性和刷细胞学检查提供了一个有用的工具,可用于识别那些罹患胆管癌高风险的PSC患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号